John Rex, Author at AMR.Solutions

PACE: GBP 6m call for early-stage Gram-negative products

Dear All, PACE (Pathways to Antimicrobial Clinical Efficacy), a large UK-based public-private funder, have announced a £6 million funding round for projects in the hit-to-lead and lead optimization stages. The call is for antibacterial projects that target WHO priority Gram-negative pathogens (Enterobacteriaceae, A. baumannii and P. aeruginosa; see the AMR.Solutions summary of the priority pathogen

1 October 2025 No Comments

EU’s €253 million, 10-year One Health AMR (OHAMR) Initiative

Dear All, The EU have today announced the European Partnership on One Health AMR (OHAMR), a major AMR funding initiative that will run for 10 years (press release, webpage)! As a bit of background, the EU have invested more than EUR 1 billion in hundreds of AMR-focused projects over the past ~15 years. From my

23 September 2025 No Comments

De-risking vaccine development: Insights spanning decades of experience

Dear All (with thanks to Vega Masignani for co-authoring this newsletter), While the work needed to create new antibacterial agents is the primary topic of this newsletter, the need for vaccines of all types is definitely part of our community’s joint remit. As discussed in the 29 Mar 2021 newsletter (“Vaccines to turn back the

21 September 2025 No Comments

20 Nov 2025: BARDA Innovation Symposium

Dear All, I am pleased to learn that BARDA is holding a one-day innovation symposium on 20 Nov 2025. As you know, BARDA is a consistently creative funder of diverse medical countermeasures, including new antibiotics. For background, see these prior newsletters: 22 Jul 2025 newsletter: “BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection” 5 Nov

20 September 2025 No Comments

The 37,000-year view: Infections in Eurasia

Dear All (prepare for something that is delightfully different and marvelously wonkish AND with thanks to Lance Price for co-authoring this newsletter), Continuing with the theme in the 15 Aug 2025 newsletter (“Global livestock resistome: Antibiotic resistance is widespread!”) of ways to use sequencing of samples from the environment, we have today an amazing paper in

17 September 2025 No Comments

Progress (at least some!) towards a global pull incentive

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), In the wake of the Sep 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR), it has been encouraging to see the continued discussion around Push and Pull incentives for antibacterial innovation and access (see the AMR.Solutions post-UNGA webpage for

15 September 2025 No Comments

Sign the 2025 Davos Compact to drive global work on AMR!

Dear All, As a follow-on to the global commitments made during the 2024 UN General Assembly High-Level Meeting on AMR (UNGA 2024 HLM AMR), the Global Future Council on AMR of the World Economic Forum (WEF) authored the 2025 Davos Compact on AMR with review by the Quadripartite Joint Secretariate on AMR as a way for organizations to

2 September 2025 No Comments

Australia calls for Subscription (“Netflix”) models: Report and podcast

Dear All, With thanks to alert reader Liam Sharkey, a post-doc in Melbourne, for the heads-up on this topic, I am very pleased to see the 17 June 2025 report from Australia entitled “Fighting Superbugs: A Subscription-Style Reimbursement Mechanism to Boost Australia’s Arsenal of Antimicrobial Medicines.” This paper is the output from a Nov 2024 roundtable in Canberra

21 August 2025 No Comments

Global livestock resistome: Antibiotic resistance is widespread!

Dear All (and with thanks to Lance Price for co-authoring this deeply wonkish newsletter), Today we turn to the idea of examining livestock manure for the presence of antibiotic resistance genes. You can easily see how this idea plays into the question of how to track and control AMR. Before we dive into the paper, however,

15 August 2025 No Comments

$ Impact of AMR in your country: Interactive web tool!

Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a report by Anthony McDonnell and a team led by the Center for Global Development in which they created economic estimates of the costs/values of action (and inaction) through 2050, based on 5 possible action/ inaction scenarios.

14 August 2025 No Comments

AMR.Solutions

John Rex